The purpose of the AMI-PONT trial is to assess whether the results in term of graft patency
with a novel coronary artery bypass (CABG) strategy, including a saphenous vein bridge to
distribute the arterial flow of the left anterior mammary artery (LIMA) to all the
anterolateral territory, are not inferior than a conventional CABG strategy combining
separated LIMA graft to left anterior descending coronary and vein graft for other target
vessels of the anterolateral territory.